Current Research Studies

Cancer – AAML1531: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Condition or Therapy:

Acute Myeloid Leukemia (AML), Down syndrome


Cancer and Blood Disorders
Study Number: AAML1531

What is the goal of this study?

This study assesses response-based chemotherapy in treating newly diagnosed acute myeloid leukemia in patients with Down syndrome.

Who can join the study?

This study may be a good fit for children and young adults who:

  • are between 21 days and 3 years old,
  • have Down syndrome, and
  • have previously untreated de novo AML.

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Douglas Hawkins